“…Thus, folic acid has been used as a targeting ligand to deliver therapeutic agents to cancer cells due to its high binding affinity to folate receptors, low immunogenicity, ease of modification, small size and functional stability (Park et al, 2005). Several folate-drug conjugates have been reported in the literatures, such as folate-low molecular weight drugs , Aronov et al, 2003, Satyam, 2008, folate-liposomes (Gabizon et al, 2004, Shi et al, 2002, Wu et al, 2006, Xiang et al, 2008, folate-gene vectors (Kim et al, 2007, Liang et al, 2008, Yoshida et al, 2006, folate-nanoparticles (Pan andFeng, 2008, Chen et al, 2008), folate-micelles (Park et al, 2005, Alemdaroglu et al, 2008, Kim et al, 2008, Yang et al, 2008, Chu et al, 2009, folate-prodrugs (Henne et al, 2006, Suzuki et al, 2007, Cavallaro et al, 2006, folate-imaging agents (KE et al, 2004.…”